Hendriks Yvonne M C, Jagmohan-Changur Shantie, van der Klift Heleen M, Morreau Hans, van Puijenbroek Marjo, Tops Carli, van Os Theo, Wagner Anja, Ausems Margreet G F M, Gomez Encarna, Breuning Martijn H, Bröcker-Vriends Annette H J T, Vasen Hans F A, Wijnen Juul Th
Center for Human and Clinical Genetics, Leiden University Medical Center, The Netherlands.
Gastroenterology. 2006 Feb;130(2):312-22. doi: 10.1053/j.gastro.2005.10.052.
BACKGROUND & AIMS: The role of the mismatch repair gene PMS2 in hereditary nonpolyposis colorectal carcinoma (HNPCC) is not fully clarified. To date, only 7 different heterozygous truncating PMS2 mutations have been reported in HNPCC-suspected families. Our aim was to further assess the role of PMS2 in HNPCC.
We performed Southern blot analysis in 112 patients from MLH1-, MSH2-, and MSH6-negative HNPCC-like families. A subgroup (n = 38) of these patients was analyzed by denaturing gradient gel electrophoresis (DGGE). In a second study group consisting of 775 index patients with familial colorectal cancer, we performed immunohistochemistry using antibodies against MLH1, MSH2, MSH6, and PMS2 proteins. In 8 of 775 tumors, only loss of PMS2 expression was found. In these cases, we performed Southern blot analysis and DGGE. Segregation analysis was performed in the families with a (possibly) deleterious mutation.
Seven novel mutations were identified: 4 genomic rearrangements and 3 truncating point mutations. Three of these 7 families fulfill the Amsterdam II criteria. The pattern of inheritance is autosomal dominant with a milder phenotype compared with families with pathogenic MLH1 or MSH2 mutations. Microsatellite instability and immunohistochemical analysis performed in HNPCC-related tumors from proven carriers showed a microsatellite instability high phenotype and loss of PMS2 protein expression in all tumors.
We show that heterozygous truncating mutations in PMS2 do play a role in a small subset of HNPCC-like families. PMS2 mutation analysis is indicated in patients diagnosed with a colorectal tumor with absent staining for the PMS2 protein.
错配修复基因PMS2在遗传性非息肉病性结直肠癌(HNPCC)中的作用尚未完全阐明。迄今为止,在疑似HNPCC的家族中仅报道了7种不同的杂合性截短PMS2突变。我们的目的是进一步评估PMS2在HNPCC中的作用。
我们对来自MLH1、MSH2和MSH6阴性的HNPCC样家族的112例患者进行了Southern印迹分析。对其中一个亚组(n = 38)的患者进行了变性梯度凝胶电泳(DGGE)分析。在由775例家族性结直肠癌索引患者组成的第二个研究组中,我们使用抗MLH1、MSH2、MSH6和PMS2蛋白的抗体进行了免疫组织化学分析。在775个肿瘤中的8个中,仅发现PMS2表达缺失。在这些病例中,我们进行了Southern印迹分析和DGGE。对具有(可能)有害突变的家族进行了分离分析。
鉴定出7种新突变:4种基因组重排和3种截短点突变。这7个家族中有3个符合阿姆斯特丹II标准。与具有致病性MLH1或MSH2突变的家族相比,其遗传模式为常染色体显性遗传,表型较轻。对经证实的携带者的HNPCC相关肿瘤进行的微卫星不稳定性和免疫组织化学分析显示,所有肿瘤均具有高微卫星不稳定性表型和PMS2蛋白表达缺失。
我们表明,PMS2中的杂合性截短突变确实在一小部分HNPCC样家族中起作用。对于诊断为结直肠癌且PMS2蛋白染色缺失的患者,建议进行PMS2突变分析。